Group A(n = 14) | Group B(n = 11) | Ρ | |
---|---|---|---|
Gender, Male | 9(64.3%) | 7(63.6) | 1.000 |
Age(years) | 69.36 ± 5.92 | 66.91 ± 7.89 | 0.384 |
Admission weight (kg) | 62.14 ± 10.26 | 63.00 ± 10.92 | 0.842 |
Admission BMI (kg/m2) | 22.29 ± 2.97 | 21.82 ± 3.06 | 0.703 |
Diabetes | 6(42.9%) | 4(36.4%) | 1.000 |
KPS scores | 92.86 ± 4.69 | 92.73 ± 4.67 | 0.946 |
Albumin levels (g/L) | 44.50 ± 5.37 | 46.64 ± 5.55 | 0.341 |
Absolute lymphocyte counts (109/L) | 1.96 ± 0.62 | 1.87 ± 0.60 | 0.732 |
Alanine aminotransferase (IU/L) | 48.50 ± 9.72 | 42.18 ± 8.16 | 0.097 |
Aspartate aminotransferase (IU/L) | 30.93 ± 9.80 | 37.18 ± 10.32 | 0.135 |
Blood urea nitrogen (mmol/L) | 6.15 ± 1.71 | 6.30 ± 1.35 | 0.814 |
Creatinine (umol/L) | 77.03 ± 10.28 | 82.14 ± 11.50 | 0.254 |
Tumor location, n(%) | |||
Middle section | 7(50%) | 8(72.8%) | 0.284 |
Lower section | 5(35.8%) | 1(9%) | |
Middle and lower sections | 2(14.3%) | 2(18.2%) | |
Tumor stage, n(%) | |||
Stage I | 4(28.6%) | 2(18.2%) | 0.200 |
Stage II | 4(28.6%) | 7(63.6%) | |
Stage III | 6(42.8%) | 2(18.2%) |